IMR Press / FBL / Volume 8 / Issue 5 / DOI: 10.2741/926

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Clinical management of chronic Chagas cardiomyopathy
Show Less
1 Departamento de Clinica Medica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Avenida Alfredo Balena, 190, Belo Horizonte, MG, Brazil
2 Chagas Disease Outpatients Clinic, Centro de Tratamento e Referência em Doenças Infecciosas e Parasitárias, Alameda Álvaro Celso 401-A, Belo Horizonte, MG, Brazil
3 Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte, MG, Brazil

Academic Editor: Herbert B. Tanowitz

Front. Biosci. (Landmark Ed) 2003, 8(5), 44–54;
Published: 1 January 2003
(This article belongs to the Special Issue Infectious diseases of the myocardium)

Chagas disease is caused by a protozoan parasite, Trypanosoma cruzi, and infects over 15 million people worldwide. New cases of the disease are now uncommon, mainly due to national control programs in Latin America. However, there is a large reservoir of chronically infected patients, many of whom will develop chagasic cardiopathy. Here, the clinical diagnosis and management of Chagas cardiopathy are discussed. Particular emphasis is placed on the clinical staging of patients and the use of various diagnostic tests that may be useful in individualizing treatment of the two most relevant clinical syndromes, ie. heart failure and arrhythmias. Finally, the relevance of specific treatment is discussed, stressing the important role of parasite persistence for disease pathogenesis.

Back to top